NCT02845856

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Fuda Cancer Hospital, Guangzhou · Academic / Other
• Sex: All
• Age: 30 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is the safety and efficacy of Cetuximab plus natural killer(NK) immunotherapy to recurrent non-small cell lung cancer with EGFR mutation.

Detailed description

By enrolling patients with lung cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Cetuximab and NK cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Conditions

• Recurrent Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Cetuximab	400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
BIOLOGICAL	NK immunotherapy	For each procedure, 10 billion cells will be infused in 4 times

Timeline

• Start date: 2016-07-01
• Primary completion: 2017-07-01
• Completion: 2019-07-01
• First posted: 2016-07-27
• Last updated: 2019-09-12

Locations

1 site across 1 country: China